ライフサイエンスコーパス: plasminogen activator inhibitor

1 bronectin 1 (P<0.0001), perforin (P=0.0002), plasminogen activator inhibitor 1 (P=0.0002), transformi

2 HOE-140 also abolished the increase in plasminogen activator inhibitor 1 (PAI-1) antigen observ

3 the protective and proliferative effects of plasminogen activator inhibitor 1 (PAI-1) deficiency aft

4 ates the interaction between vitronectin and plasminogen activator inhibitor 1 (PAI-1) in a variety o

5 Plasminogen activator inhibitor 1 (PAI-1) is a serpin in

6 Transcriptional regulation of plasminogen activator inhibitor 1 (PAI-1) is of particul

7 c TGF-beta1 mRNA, tissue hydroxyproline, and plasminogen activator inhibitor 1 (PAI-1) levels were si

8 potent and selective synthetic antagonist of plasminogen activator inhibitor 1 (PAI-1) that preserved

9 (MS, n = 20; control, n = 10), expression of plasminogen activator inhibitor 1 (PAI-1), a key enzyme

10 hich H. pylori upregulates the expression of plasminogen activator inhibitor 1 (PAI-1), a member of t

11 of JNK and p38 as well as the expression of plasminogen activator inhibitor 1 (PAI-1), a TGF-beta-re

12 diated proteolysis, which is counteracted by plasminogen activator inhibitor 1 (PAI-1), another secre

13 vator (tPA) and its physiological inhibitor, plasminogen activator inhibitor 1 (PAI-1), in Puumala ha

14 with diabetes experience elevated levels of plasminogen activator inhibitor 1 (PAI-1), regardless of

15 The aim of this study is to evaluate serum plasminogen activator inhibitor 1 (PAI-1), tumor necrosi

16 VFA and higher plasma IL-6, adiponectin, and plasminogen activator inhibitor 1 (PAI-1).

17 isolated a high-quality DNA aptamer pair for plasminogen activator inhibitor 1 (PAI-1).

18 ral function for the gene SERPINE1, encoding plasminogen activator inhibitor 1 (PAI-1).

19 The most upregulated gene identified encodes plasminogen activator inhibitor 1 (PAI-1, Serpine 1), a

20 Plasminogen activator inhibitor 1 (PAI-1/serpinE1) can b

21 xpression of the TGFbeta-regulated promoters plasminogen activator inhibitor 1 and 3TP, increased Sma

22 owed less fibrosis and blocked expression of plasminogen activator inhibitor 1 and osteopontin 1.

23 Transcriptional changes in the Tgf-beta1 and plasminogen activator inhibitor 1 gene products were mea

24 Increased activated plasminogen activator inhibitor 1 had a strong associati

25 king BDNF maturation in the hippocampus with plasminogen activator inhibitor 1 hinders the persistenc

26 s and levels of the coagulation intermediary plasminogen activator inhibitor 1 in three mouse models

27 plasminogen activator and elevated levels of plasminogen activator inhibitor 1 were observed.

28 as observed, but a trend toward lower plasma plasminogen activator inhibitor 1 with higher excretion

29 ent with earlier reports (thrombomodulin and plasminogen activator inhibitor 1), and 15 were new disc

30 ion of inflammatory mediators such as PAI-1 (plasminogen activator inhibitor 1), suggesting that gluc

31 Tests for FXI and FXII activity, plasminogen activator inhibitor 1, and activated partial

32 receptor 2, urokinase plasminogen activator, plasminogen activator inhibitor 1, and certain multipara

33 lammatory cytokines such as TNF-alpha, IL-6, plasminogen activator inhibitor 1, and IL-1beta.

34 1-mediated induction of fibronectin, Snail1, plasminogen activator inhibitor 1, and matrix metallopro

35 lammatory markers were then studied (sCD40L, plasminogen activator inhibitor 1, antithrombin III, and

36 whereas downregulation of thrombomospondin, plasminogen activator inhibitor 1, or connective tissue

37 tor, but did not influence thrombomospondin, plasminogen activator inhibitor 1, or connective tissue

38 lesterol, P < .001; triglycerides, P < .001; plasminogen activator inhibitor 1, P for trend = .04; an

39 Increased transcription of the genes for plasminogen activator inhibitor 1, Tgf-beta1, Tgf-beta-i

40 Plasminogen activator inhibitor 1, vascular cell adhesio

41 r slows down matrix degradation by increased plasminogen activator inhibitor 1.

42 tor and histidine-rich glycoprotein, but not plasminogen activator inhibitors 1 and 2.

43 asma tissue plasminogen activator (t-PA) and plasminogen-activator inhibitor 1 antigen and activity c

44 aused similar (p = NS) increases in inactive plasminogen-activator inhibitor 1 in both smokers and no

45 binding (P<0.0001) without affecting plasma plasminogen-activator inhibitor 1 or von Willebrand fact

46 d plasma tissue plasminogen activator (tPA), plasminogen-activator inhibitor 1, and von Willebrand fa

47 the role of the serine proteinase inhibitor plasminogen activator inhibitor -1 (PAI-1) in facilitati

48 in complex, tissue plasminogen activator and plasminogen activator inhibitor-1 (markers for fibrinoly

49 combined therapy attenuated the formation of plasminogen activator inhibitor-1 (p < 0.05), IL-1beta,

50 Higher plasminogen activator inhibitor-1 (p = 0.002), E-selecti

51 Similarly, higher plasminogen activator inhibitor-1 (p = 0.007) and S100B

52 Plasminogen activator inhibitor-1 (P=0.014), interleukin

53 n), factor VII G10976A, prothrombin G20210A, plasminogen activator inhibitor-1 (PAI-1) [-675] 4G/5G,

54 ay inhibitor (TFPI) expression and increased plasminogen activator inhibitor-1 (PAI-1) activity in th

55 n TGF-beta-induced Smad3 phosphorylation and plasminogen activator inhibitor-1 (PAI-1) and cyclooxyge

56 ide new evidence that both overexpression of plasminogen activator inhibitor-1 (PAI-1) and elevated c

57 n of incident diabetes to dynamic changes of plasminogen activator inhibitor-1 (PAI-1) and fibrinogen

58 -beta1 induces transcriptional activation of plasminogen activator inhibitor-1 (PAI-1) and growth inh

59 catabolism is increased after inhibition of plasminogen activator inhibitor-1 (PAI-1) and may consti

60 ve systematically examined the affinities of plasminogen activator inhibitor-1 (PAI-1) and proteinase

61 l transition (EMT), TNBC cells could produce plasminogen activator inhibitor-1 (PAI-1) and stimulate

62 n effects, including increased production of plasminogen activator inhibitor-1 (PAI-1) and tissue fac

63 Concentrations of OPN, as well as plasminogen activator inhibitor-1 (PAI-1) and vascular e

64 intimal growth through early upregulation of plasminogen activator inhibitor-1 (PAI-1) and, subsequen

65 mostatic markers of endothelial dysfunction, plasminogen activator inhibitor-1 (PAI-1) antigen, and v

66 ctivatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor-1 (PAI-1) are causal fac

67 Plasma levels of plasminogen activator inhibitor-1 (PAI-1) are elevated i

68 Vitronectin and plasminogen activator inhibitor-1 (PAI-1) are important

69 Vitronectin and plasminogen activator inhibitor-1 (PAI-1) are proteins t

70 In vitro, TSP1 acutely induces expression of plasminogen activator inhibitor-1 (PAI-1) by monocytic c

71 asure tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) by real-time P

72 The inactivation of plasminogen activator inhibitor-1 (PAI-1) by the small m

73 ons between genetic variants and circulating plasminogen activator inhibitor-1 (PAI-1) concentration,

74 adherin and induced Snail1, fibronectin, and plasminogen activator inhibitor-1 (PAI-1) expression.

75 onsensus XRE (NC-XRE) in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene that recr

76 Plasminogen activator inhibitor-1 (PAI-1) has been impli

77 y binding site in human vitronectin (VN) for plasminogen activator inhibitor-1 (PAI-1) has been local

78 While the pathogenesis of VOD is uncertain, plasminogen activator inhibitor-1 (PAI-1) has emerged as

79 epidermal growth factor receptor (EGFR) and plasminogen activator inhibitor-1 (PAI-1) have a shorter

80 The role of plasminogen activator inhibitor-1 (PAI-1) in angiogenesi

81 Although the involvement of plasminogen activator inhibitor-1 (PAI-1) in fibrotic di

82 Basal expression of plasminogen activator inhibitor-1 (PAI-1) in human and m

83 ited MKK3-p38 kinase-dependent expression of plasminogen activator inhibitor-1 (PAI-1) in lung, there

84 Recent studies suggest a crucial role for plasminogen activator inhibitor-1 (PAI-1) in mediating s

85 fect of intracerebroventricular injection of plasminogen activator inhibitor-1 (PAI-1) in rat pups su

86 Levels of plasminogen activator inhibitor-1 (PAI-1) increased sign

87 en activator (uPA), its receptor (uPAR), and plasminogen activator inhibitor-1 (PAI-1) into the early

88 Plasminogen activator inhibitor-1 (PAI-1) is a biomarker

89 Plasminogen activator inhibitor-1 (PAI-1) is an importan

90 Plasminogen activator inhibitor-1 (PAI-1) is increased i

91 Plasminogen activator inhibitor-1 (PAI-1) is known to mo

92 Plasminogen activator inhibitor-1 (PAI-1) is known to pr

93 Plasminogen activator inhibitor-1 (PAI-1) is the main in

94 okinase-type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) levels in the

95 he morning surge of the prothrombotic factor plasminogen activator inhibitor-1 (PAI-1) observed in hu

96 gands specific to alpha-helix F (alphaHF) of plasminogen activator inhibitor-1 (PAI-1) on the stoichi

97 king p53 (p53-/-) express minimal amounts of plasminogen activator inhibitor-1 (PAI-1) protein as wel

98 TGF-beta1 activity was evaluated using a plasminogen activator inhibitor-1 (PAI-1) reporter trans

99 glomerular fibrin deposition and glomerular plasminogen activator inhibitor-1 (PAI-1) staining than

100 iation of a gain-of-function polymorphism in plasminogen activator inhibitor-1 (PAI-1) with airway ob

101 Elevated levels of plasminogen activator inhibitor-1 (PAI-1), a potent inhi

102 Deficiency in plasminogen activator inhibitor-1 (PAI-1), an endogenous

103 t gene SERPINE1 that is encoding the protein plasminogen activator inhibitor-1 (PAI-1), an establishe

104 Plasma and tissue levels of plasminogen activator inhibitor-1 (PAI-1), an inhibitor

105 y expressed increased basal levels of SPARC, plasminogen activator inhibitor-1 (PAI-1), and active be

106 , vascular endothelial growth factor (VEGF), plasminogen activator inhibitor-1 (PAI-1), and endotheli

107 NADPH oxidases (NOXs), and fibrotic markers, plasminogen activator inhibitor-1 (PAI-1), and fibronect

108 VEGF, plasminogen activator inhibitor-1 (PAI-1), and pigment e

109 nase-9 (MMP-9), tumor necrosis factor-alpha, plasminogen activator inhibitor-1 (PAI-1), and urinary o

110 ese changes paralleled reduced expression of plasminogen activator inhibitor-1 (PAI-1), PDGF-B (PDGF-

111 ed for seven adipokines-adiponectin, leptin, plasminogen activator inhibitor-1 (PAI-1), resistin, hep

112 In infected mice that overexpress plasminogen activator inhibitor-1 (PAI-1), S. aureusclfA

113 ctor receptors (sTNFR-I and -II), protein C, plasminogen activator inhibitor-1 (PAI-1), surfactant pr

114 investigated the relationship of ceramide to plasminogen activator inhibitor-1 (PAI-1), the primary i

115 Plasminogen activator inhibitor-1 (PAI-1), which inhibit

116 the inactivation of tPA and two chain uPA by plasminogen activator inhibitor-1 (PAI-1), which is pote

117 leomycin failed to induce miR-34a in p53- or plasminogen activator inhibitor-1 (PAI-1)-deficient mice

118 76.5% decrease; P<0.01), whereas hearts from plasminogen activator inhibitor-1 (PAI-1)-null mice rele

119 and both proteases are inhibited rapidly by plasminogen activator inhibitor-1 (PAI-1).

120 tions and is characterized by high levels of plasminogen activator inhibitor-1 (PAI-1).

121 een shown that ethanol induces activation of plasminogen activator inhibitor-1 (PAI-1).

122 asminogen activator (tPA), and up-regulating plasminogen activator inhibitor-1 (PAI-1).

123 xia-inducible factor-1alpha (HIF-1alpha) and plasminogen activator inhibitor-1 (PAI-1).

124 generate breakdown products of matrix-bound plasminogen activator inhibitor-1 (PAI-1).

125 ata for the latency transition of the serpin plasminogen activator inhibitor-1 (PAI-1).

126 Polymorphisms in plasminogen activator inhibitor-1 (PAI-1, SERPINE1) and

127 cript, identified by mRNA profiling, encoded plasminogen activator inhibitor-1 (PAI-1; SERPINE1).

128 upling of TGF-beta to Smad2/3 activation and plasminogen activator inhibitor-1 (PAI1) expression, whi

129 the enzyme x inhibitor complex of tcu-PA and plasminogen activator inhibitor-1 (tcu-PA.PAI-1).

130 ), inflammation (IL-6), or antifibrinolysis (plasminogen activator inhibitor-1 [PAI-1]) contribute to

131 P], renin, aldosterone), hemostatic factors (plasminogen activator inhibitor-1 [PAI-1]), inflammation

132 ad decreased ADAMTS-13 activity, but similar plasminogen activator inhibitor-1 activity and prothromb

133 Plasminogen activator inhibitor-1 also induced neurite e

134 Higher circulating plasminogen activator inhibitor-1 and aldosterone levels

135 On backward elimination, plasminogen activator inhibitor-1 and aldosterone remain

136 Plasminogen activator inhibitor-1 and C-reactive protein

137 Adjusting for S100B did not alter plasminogen activator inhibitor-1 and E-selectin associa

138 mes and hyperfibrinolysis with low levels of plasminogen activator inhibitor-1 and high D-dimer level

139 and mRNA expression of profibrotic markers: plasminogen activator inhibitor-1 and monocyte chemotact

140 TGF-beta signaling through up-regulation of plasminogen activator inhibitor-1 and phosphorylation of

141 both murine models while decreasing alveolar plasminogen activator inhibitor-1 and promoting myofibro

142 Plasminogen activator inhibitor-1 and protein C had a sy

143 Measurement of plasminogen activator inhibitor-1 and protein-C levels m

144 nd was completely abrogated by the urokinase plasminogen activator inhibitor-1 and serine protease in

145 ass index, such that the increased levels of plasminogen activator inhibitor-1 and soluble VCAM-1 ass

146 odest phenotypes, but mice deficient in both plasminogen activator inhibitor-1 and thrombin-activatab

147 ed expression of the prothrombotic molecules plasminogen activator inhibitor-1 and tissue factor (TF)

148 sal expression of alpha-smooth muscle actin, plasminogen activator inhibitor-1 and transforming growt

149 Preincubation of vitronectin with plasminogen activator inhibitor-1 eliminated its ability

150 tion, proliferation, collagen synthesis, and plasminogen activator inhibitor-1 expression in cardiac

151 ase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 expression was predomi

152 with increased alpha-smooth muscle actin and plasminogen activator inhibitor-1 expression.

153 e liver by 2 hours, and the concentration of plasminogen activator inhibitor-1 in plasma increased be

154 easurement of plasma levels of protein C and plasminogen activator inhibitor-1 in plasma samples that

155 h enalapril or losartan also decreased renal plasminogen activator inhibitor-1 in TSLPtg mice, assess

156 s by infusion of blocking antibodies against plasminogen activator inhibitor-1 led to decreased lung-

157 ctivity were decreased due to an increase in plasminogen activator inhibitor-1 levels in transfusion-

158 matrix metalloproteinase (MMP)-8, MMP-9, and plasminogen activator inhibitor-1 levels were determined

159 eline protein-C levels were low and baseline plasminogen activator inhibitor-1 levels were elevated i

160 nce of circulating alteplase and recovery of plasminogen activator inhibitor-1 levels within 2 hours

161 e (including procollagen I, TGF-beta(1), and plasminogen activator inhibitor-1 mRNA), suggesting that

162 Conversely, treatment with plasminogen activator inhibitor-1 or neutralizing antibo

163 Mice deficient in plasminogen activator inhibitor-1 or thrombin-activatabl

164 ation of Smads 2 and 3 and activation of the plasminogen activator inhibitor-1 promoter (in NRP-154 a

165 sed transforming growth factor-beta-mediated plasminogen activator inhibitor-1 promoter activity in o

166 pitation showed reduced Smad3 binding to the plasminogen activator inhibitor-1 promoter in PTCs treat

167 on involves a functional polymorphism of the plasminogen activator inhibitor-1 promoter region and me

168 y reduced transactivation potential with the plasminogen activator inhibitor-1 promoters and behaved

169 tissue inhibitor of metalloproteinase-1 and plasminogen activator inhibitor-1 secretion in MDA-MB-23

170 S-1 peptide had increased efficacy in plasminogen activator inhibitor-1 serpin-deficient trans

171 of protein C and increased plasma levels of plasminogen activator inhibitor-1 that are independent r

172 addition, the use of exosites by maspin and plasminogen activator inhibitor-1 to indirectly affect p

173 mediated connective tissue growth factor and plasminogen activator inhibitor-1 up-regulation.

174 In contrast, both LOX-1 and CD32 mediate plasminogen activator inhibitor-1 upregulation in arteri

175 ed to augmented pressure (P=0.0003), whereas plasminogen activator inhibitor-1 was positively associa

176 mponents (analyzed as continuous variables), plasminogen activator inhibitor-1 was significantly and

177 Changes in interleukin-1B and plasminogen activator inhibitor-1 were apparent 24 hours

178 mplexes, plasminogen activator activity, and plasminogen activator inhibitor-1 were determined by mea

179 variate analysis, lower protein C and higher plasminogen activator inhibitor-1 were strong independen

180 vation with pan-arterial vascular stiffness, plasminogen activator inhibitor-1 with central vascular

181 of prometastatic (i.e. cyclooxygenase-2 and plasminogen activator inhibitor-1) and prosurvival (i.e.

182 oatrial natriuretic peptide, fibrinogen, and plasminogen activator inhibitor-1) in nonobese Framingha

183 Inhibition of uPA activity with natural (plasminogen activator inhibitor-1) or synthetic (amilori

184 There was a 51.8% net decrease in PAI-1 (plasminogen activator inhibitor-1), a 12.1% net decrease

185 (D-dimer, tissue-type plasminogen activator, plasminogen activator inhibitor-1), and inflammation (in

186 eactive protein), hemostasis (fibrinogen and plasminogen activator inhibitor-1), neurohormonal activa

187 C-reactive protein), hemostasis (D-dimer and plasminogen activator inhibitor-1), neurohormonal activi

188 s is either weak (interleukin-8) or delayed (plasminogen activator inhibitor-1).

189 crease in interleukin-8, a 21.4% decrease in plasminogen activator inhibitor-1, a 51.3% decrease in t

190 n of CAGE led to the decreased expression of plasminogen activator inhibitor-1, a TGFbeta-responsive

191 evented CRP-induced arteriolar expression of plasminogen activator inhibitor-1, a thrombogenic protei

192 issue repair and vascular integrity, such as plasminogen activator inhibitor-1, activin A, and cystei

193 c peptide) and lower blood concentrations of plasminogen activator inhibitor-1, aldosterone, C-reacti

194 -regulation of the production and release of plasminogen activator inhibitor-1, an inhibitor of the p

195 to a reduction in the proteolytic inhibitor, plasminogen activator inhibitor-1, and an associated thr

196 ndividually, C-reactive protein, fibrinogen, plasminogen activator inhibitor-1, and ARR were related

197 1+2, fibrinogen, thrombomodulin, protein C, plasminogen activator inhibitor-1, and D-dimers.

198 protein cholesterol, albumin excretion rate, plasminogen activator inhibitor-1, and hemoglobin A1c le

199 d2 phosphorylation, normalized expression of plasminogen activator inhibitor-1, and mitigated PH and

200 lammatory markers, e.g., C-reactive protein, plasminogen activator inhibitor-1, and other cytokines,

201 s of insulin, triglycerides, blood pressure, plasminogen activator inhibitor-1, and the ratio of tota

202 pression of interleukin-6, thrombospondin-1, plasminogen activator inhibitor-1, and tissue factor, wh

203 associated with inhibition of TGF-beta1 and plasminogen activator inhibitor-1, and with a significan

204 4, a protein with relevant interactions with plasminogen activator inhibitor-1, angiogenesis, and wou

205 6, endothelin-1, matrix metalloproteinase-9, plasminogen activator inhibitor-1, Bax and caspase-3, pr

206 We measured plasma concentrations of plasminogen activator inhibitor-1, E-selectin, and angio

207 flammation (C-reactive protein), hemostasis (plasminogen activator inhibitor-1, fibrinogen), neurohor

208 etic peptide and B-type natriuretic peptide, plasminogen activator inhibitor-1, fibrinogen, and homoc

209 on of genes downstream of Smad2/3, including plasminogen activator inhibitor-1, fibronectin, and conn

210 assays for 6 biomarkers (C-reactive protein, plasminogen activator inhibitor-1, homocysteine, aldoste

211 d expression of TGF-beta downstream targets (plasminogen activator inhibitor-1, parathyroid hormone-r

212 asmin complex, tissue plasminogen activator, plasminogen activator inhibitor-1, protein C, antithromb

213 ng strand 1C observed in a prelatent form of plasminogen activator inhibitor-1, since the (1)H NMR sp

214 matrix metalloproteinase-9, myeloperoxidase, plasminogen activator inhibitor-1, soluble E-selectin, s

215 tronectin was enhanced by uPA and blocked by plasminogen activator inhibitor-1, the latter approach a

216 ingosine, and S1P induced gene expression of plasminogen activator inhibitor-1, TNF-alpha, monocyte c

217 tasis, including TWIST1, fibronectin (FN)-1, plasminogen activator inhibitor-1, urokinase-type plasmi

218 uinating enzyme, represses the expression of plasminogen activator inhibitor-1, which is critical in

219 ependent connective tissue growth factor and plasminogen activator inhibitor-1-induced proliferative

220 xpression of the endogenous Smad target gene plasminogen activator inhibitor-1.

221 ue growth factor, collagen-alpha1[Iota], and plasminogen activator inhibitor-1.

222 or pathway inhibitor, fibrinogen-like 1, and plasminogen activator inhibitor-1.

223 nd to S195A tPA that is already complexed to plasminogen activator inhibitor-1.

224 ants without affecting the protein levels of plasminogen activator inhibitor-1.

225 pus by inducing expression of its inhibitor, plasminogen activator inhibitor-1.

226 ssociated with impeded fibrinolysis, such as plasminogen activator inhibitor-1.

227 s, such as beta-galactosidase (beta-Gal) and plasminogen activator inhibitor-1.

228 nectin, X-linked inhibitor of apoptosis, and plasminogen activator inhibitor-1.

229 y upregulating the serine protease inhibitor plasminogen activator inhibitor-1.

230 in 6 patients, protein S deficiency in 4, a plasminogen-activator inhibitor-1 (PAI-1) deficiency in

231 orylation results in inducible expression of plasminogen activator inhibitor-2 (PAI-2), a member of t

232 Expression of the plasminogen activator inhibitor-2 (PAI-2/SERPINB2) was h

233 In the absence of one antiapoptotic protein, plasminogen activator inhibitor-2, host cell death incre

234 egulation of genes encoding proteins such as plasminogen activator inhibitors and matrix metalloprote

235 n-10), coagulation (antithrombin, factor IX, plasminogen activator inhibitor, d-dimer, thrombin antit

236 lar matrix accumulation and increased PAI-1 (plasminogen activator inhibitor) expression.

237 covered roles for plasminogen activators and plasminogen activator inhibitors in these diseases provi

238 r, plasmin-alpha2-antiplasmin complexes, and plasminogen activator inhibitor) or the release of pro-

239 ), a specific marker for myofibroblasts, and plasminogen activator inhibitor (PAI), a protein involve

240 tissue factor pathway inhibitor, protein C, plasminogen activator inhibitor (PAI), and thrombin-anti

241 h complete prevention of the upregulation of plasminogen activator inhibitor (PAI)-1 caused by ethano

242 of urokinase plasminogen activator (uPA) and plasminogen activator inhibitor (PAI)-1 in 2 murine mamm

243 Recent studies demonstrating a role for plasminogen activator inhibitor (PAI)-1 in cholestatic l

244 8, macrophage chemoattractant protein-1, and plasminogen activator inhibitor (PAI)-1 mRNA (r >/= 0.46

245 effect on plaque growth, we used a truncated plasminogen activator inhibitor (PAI)-1 protein, rPAI-1(

246 hesion molecules, fibrinogen-like protein 2, plasminogen activator inhibitor (PAI)-1), secretion of p

247 1 bound the promoters of tissue factor (TF), Plasminogen Activator Inhibitor (PAI)-1, and NGF-1A Bind

248 on of Jun NH2-terminal kinases, induction of plasminogen activator inhibitor (PAI)-1, and restoration

249 y stage, and urinary cell levels of mRNA for plasminogen activator inhibitor (PAI)-1, vimentin, tissu

250 n 2, tissue plasminogen activator (tPA), and plasminogen activator inhibitor (PAI)-1.

251 ghly susceptible, whereas those deficient in plasminogen activator inhibitor (PAI-1) are resistant to

252 The 4G/5G polymorphism in the plasminogen activator inhibitor (PAI-1) gene impacts tra

253 sized that lower protein C and higher type 1 plasminogen activator inhibitor (PAI-1) levels in plasma

254 Plasminogen activator inhibitor (PAI-1) levels were quan

255 ) (by confocal microscopy), plasma levels of plasminogen activator inhibitor (PAI-1), and factor XIII

256 chemotactic protein-1 (CCL2) (MCP-1), tissue plasminogen activator inhibitor (PAI-1), and regulated o

257 l inhibitor of plasminogen activator, type I plasminogen activator inhibitor (PAI-1), controls blood

258 connective tissue growth factor (CTGF), and plasminogen activator inhibitor (PAI-1).

259 ntal vascular-endothelial function [ratio of plasminogen-activator inhibitor (PAI) 1 to PAI-2 and mea

260 Plasminogen activator inhibitors (PAIs) 1 and 2 were als

261 se in adipocyte diameter (P = 0.048), plasma plasminogen activator inhibitor protein-1 (P = 0.019), v

262 s, including DNA-binding protein A, 9G8, and plasminogen activator inhibitor RNA-binding protein 1 (P

263 Recently it has been demonstrated that plasminogen activator inhibitor serpins promote brain me

264 IMD) corresponding to amino acids 350-355 of plasminogen activator inhibitor type 1 (PAI-1) abolished

265 Plasminogen activator inhibitor type 1 (PAI-1) is a majo

266 Plasminogen activator inhibitor type 1 (PAI-1) is a seri

267 Surprisingly, addition of high dose plasminogen activator inhibitor type 1 (PAI-1) to bile d

268 cellular adhesion molecule 1 (ICAM1), F4/80, plasminogen activator inhibitor type 1 (PAI-1), and type

269 novel class of small molecule inhibitors for plasminogen activator inhibitor type 1 (PAI-1), represen

270 Similarly, addition of plasminogen activator inhibitor type 1 (SERPINE1) blocke

271 complex, plasmin-alpha2-antiplasmin complex, plasminogen activator inhibitor type 1 [PAI-1], D-dimer,

272 ng tissue-type plasminogen activator [t-PA], plasminogen activator inhibitor type 1 [PAI-I]), and car

273 Plasminogen activator inhibitor type 1 antigen and activ

274 y led to (1) lower plasma insulin; (2) lower plasminogen activator inhibitor type 1 antigen and activ

275 e examined effects of co-administration of a plasminogen activator inhibitor type 1 derived peptide,

276 dex, and urokinase plasminogen activator and plasminogen activator inhibitor type 1 in specific subgr

277 r and/or the tissue plasminogen activator-to-plasminogen activator inhibitor type 1 ratio tests, to a

278 mbosis and endothelial function (D-dimer and plasminogen activator inhibitor type 1), and microvascul

279 nogen activator antigen (known to track with plasminogen activator inhibitor type 1); and (3) lower C

280 Plasminogen activator inhibitor type 1, (PAI-1) the prim

281 r-alpha, monocyte chemoattractant protein-1, plasminogen activator inhibitor type 1, and macrophage p

282 roteins (mammalian target of rapamycin, SMA, plasminogen activator inhibitor type 1, and type I colla

283 sera expressed and released higher levels of plasminogen activator inhibitor type 1, reduced levels o

284 e plasminogen activator (uPA), its inhibitor plasminogen activator inhibitor type 1, uPA receptor (uP

285 tes and proposes a crucial upstream role for plasminogen activator inhibitor type 1-dependent regulat

286 SerpinB2 or plasminogen activator inhibitor type 2 (PAI-2) is highly

287 Here we show that depletion of plasminogen activator inhibitor type 2 (PAI-2), a serine

288 SerpinB2 (plasminogen activator inhibitor type 2) is constitutivel

289 cytoprotective, Rb-binding protein SerpinB2 (plasminogen activator inhibitor type 2) protects Rb from

290 ough down-regulation of thrombospondin-1 and plasminogen activator inhibitor type 2.

291 Increased levels of plasminogen activator inhibitor type I (PAI-1) have been

292 Elevated plasma levels of plasminogen activator inhibitor type I (PAI-1), a signif

293 plasma tissue-type plasminogen activator and plasminogen activator inhibitor type I) was not influenc

294 However, adipose tissue expression of plasminogen activator inhibitor type-1 (PAI-1) and CD11

295 Plasminogen activator inhibitor type-1 (PAI-1) is a memb

296 The serine proteinase inhibitor, plasminogen activator inhibitor type-1 (PAI-1), binds to

297 Transcriptional up-regulation of the plasminogen activator inhibitor type-2 (PAI-2) gene is a

298 de, aldosterone, renin, fibrinogen, D-dimer, plasminogen-activator inhibitor type 1, and homocysteine

299 ne, renin, B-type natriuretic peptide (BNP), plasminogen-activator inhibitor type 1, fibrinogen, and

300 ddition, connective tissue growth factor and plasminogen activator inhibitor were downregulated, alon